Minimally Invasive Treatment of Vesicoureteral Reflux with Endoscopic Injection of Dextranomer/Hyaluronic Acid Copolymer: The Children’s Hospitals of Atlanta Experience

Abstract

The majority of patients (72%) undergoing minimally invasive treatment of VUR with Dx/HA are cured after 1 treatment. Contralateral treatment of nonrefluxing ureters should be considered in view of the increased incidence of new reflux (4.5%) and absence of morbidity with Dx/HA injection. There is a definite learning curve with injection therapy. The location of injected material and experience with the technique appear to correlate with the outcome of the procedure.